GlycoMimetics (GLYC) Q3 2024 earnings summary

Executive summary

• Reported a net loss of $30.7 million for the nine months ended September 30, 2024, with $14.4 million in cash and cash equivalents at period end.

• Suspended all R&D activities after Phase 3 trial of uproleselan failed to meet primary endpoint; workforce reduced by 80%.

• Entered into a merger agreement with Crescent Biopharma, expected to close in Q2 2025, with a concurrent $200 million private placement.

Financial highlights

• Net loss for Q3 2024 was $9.8 million, a 7% increase from Q3 2023; nine-month net loss increased 10% year-over-year.

• Research and development expenses decreased 68% in Q3 2024 year-over-year due to winding down operations.

• General and administrative expenses fell 11% in Q3 2024 year-over-year, mainly from lower personnel costs.

• Recorded a $1.2 million gain on sale of rivipansel and $5.0 million in severance charges related to restructuring.

• Cash used in operations was $27.4 million for the nine months ended September 30, 2024.

Outlook and guidance

• Current cash expected to fund operations only through the closing of the Crescent merger and private placement.

• If the merger does not close, alternative cash strategies or liquidation may be required.